Abcam welcomes Luba Greenwood to its Board as Non-Executive Director

– UK, Cambridge –  Abcam plc (LON: ABC | Nasdaq: ABCM), a global leader in the supply of life science research tools, today announced the appointment of Luba Greenwood to its Board as a non-executive Director with immediate effect.

“I am delighted to welcome Luba to the Board of Abcam. Luba has had a distinguished career and her experience and expertise, particularly her understanding of Life Sciences, Technology and Healthcare will be a valuable asset to the Company as we continue to partner in this area and work towards our long-term growth plans.” said Board Chairman, Peter Allen.

About Luba Greenwood

Luba’s experiences focus on business development and strategy. She is a veteran biotech, pharmaceutical, tech, and life sciences investor and company builder. Luba has held several senior leadership and board positions in the healthcare industry. Currently, she serves as the managing partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has built and launched. Luba is also the CEO of Kojin Therapeutics, a BSC portfolio company. Her previous experience includes increasing levels of responsibility at Google Life Sciences, Verily, and F. Hoffman-La Roche.

Luba has extensive board experience, and currently serves on the board of directors of the following private institutions: MassBio, BenchSci, and In8Bio, Inc.

About Abcam plc

As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission faster. The Company offers highly validated antibodies, assays, and other research tools to address important targets in critical biological pathways by providing the research and clinical communities with tools and scientific support.

Already a pioneer in data sharing and eCommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam’s worldwide customer base of approximately 750,000 life science researchers uses Abcam’s antibodies, reagents, biomarkers, and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent program of customer reviews and datasheets, combined with industry-leading validation initiatives, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.